Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
Incidence rate estimates
Invasive pneumococcal disease
Pneumococcal conjugate vaccines
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
05 09 2022
05 09 2022
Historique:
received:
11
01
2022
accepted:
17
08
2022
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Invasive pneumococcal disease (IPD) is a major cause of pediatric morbidity and mortality. Pneumococcal conjugate vaccines (PCVs) were introduced in the US in 2000 (PCV7) and 2010 (PCV13). This study estimated the annual incidence rates (IRs) and time trends of IPD to quantify the burden of disease in children before and after the introduction of PCV7 and PCV13 in the US. IPD episodes were identified in the IBM MarketScan Commercial and Medicaid Databases using claims with International Classification of Diseases 9/10 In commercially insured children, IPD IRs decreased from 9.4 to 2.8 episodes/100,000 PY between the pre-PCV7 (1998-1999) and late PCV13 period (2014-2018) overall, and from 65.6 to 11.6 episodes/100,000 PY in children < 2 years. In the Medicaid population, IPD IRs decreased from 11.3 to 4.2 episodes/100,000 PY between the early PCV7 (2001-2005) and late PCV13 period overall, and from 42.6 to 12.8 episodes/100,000 PY in children < 2 years. The trends of IRs for meningitis, bacteremia, and bacteremic pneumonia followed the patterns of overall IPD episodes. The ITS analyses indicated significant decreases in the early PCV7 period, increases in the late PCV7 and decreases in the early PCV13 period in commercially insured children overall. However, increases were also observed in the late PCV13 period in children < 2 years. The percentage of cases with underlying risk factors increased in both populations. IRs of IPD decreased from 1998 to 2018, following introduction of PCV7 and PCV13, with larger declines during the early PCV7 and early PCV13 periods, and among younger children. However, the residual burden of IPD remains substantial. The impact of future PCVs on IPD IRs will depend on the proportion of vaccine-type serotypes and vaccine effectiveness in children with underlying conditions.
Sections du résumé
BACKGROUND
Invasive pneumococcal disease (IPD) is a major cause of pediatric morbidity and mortality. Pneumococcal conjugate vaccines (PCVs) were introduced in the US in 2000 (PCV7) and 2010 (PCV13). This study estimated the annual incidence rates (IRs) and time trends of IPD to quantify the burden of disease in children before and after the introduction of PCV7 and PCV13 in the US.
METHODS
IPD episodes were identified in the IBM MarketScan Commercial and Medicaid Databases using claims with International Classification of Diseases 9/10
RESULTS
In commercially insured children, IPD IRs decreased from 9.4 to 2.8 episodes/100,000 PY between the pre-PCV7 (1998-1999) and late PCV13 period (2014-2018) overall, and from 65.6 to 11.6 episodes/100,000 PY in children < 2 years. In the Medicaid population, IPD IRs decreased from 11.3 to 4.2 episodes/100,000 PY between the early PCV7 (2001-2005) and late PCV13 period overall, and from 42.6 to 12.8 episodes/100,000 PY in children < 2 years. The trends of IRs for meningitis, bacteremia, and bacteremic pneumonia followed the patterns of overall IPD episodes. The ITS analyses indicated significant decreases in the early PCV7 period, increases in the late PCV7 and decreases in the early PCV13 period in commercially insured children overall. However, increases were also observed in the late PCV13 period in children < 2 years. The percentage of cases with underlying risk factors increased in both populations.
CONCLUSIONS
IRs of IPD decreased from 1998 to 2018, following introduction of PCV7 and PCV13, with larger declines during the early PCV7 and early PCV13 periods, and among younger children. However, the residual burden of IPD remains substantial. The impact of future PCVs on IPD IRs will depend on the proportion of vaccine-type serotypes and vaccine effectiveness in children with underlying conditions.
Identifiants
pubmed: 36064378
doi: 10.1186/s12889-022-14051-6
pii: 10.1186/s12889-022-14051-6
pmc: PMC9442936
doi:
Substances chimiques
Heptavalent Pneumococcal Conjugate Vaccine
0
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1677Informations de copyright
© 2022. The Author(s).
Références
Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S109-18
pubmed: 24336053
MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8
pubmed: 18272956
mBio. 2020 May 19;11(3):
pubmed: 32430472
Clin Infect Dis. 2020 Nov 5;71(8):e235-e243
pubmed: 31955196
Front Cell Infect Microbiol. 2021 Mar 19;11:617573
pubmed: 33869075
PLoS Med. 2013;10(9):e1001517
pubmed: 24086113
Pediatrics. 2019 Sep;144(3):
pubmed: 31420369
Lancet Infect Dis. 2015 Mar;15(3):301-9
pubmed: 25656600
Emerg Infect Dis. 2021;27(6):1627-1636
pubmed: 34013855
Annu Rev Microbiol. 2018 Sep 8;72:521-549
pubmed: 30200849
Vaccine. 2019 Jan 3;37(1):41-48
pubmed: 30478004
Lancet. 2011 Dec 3;378(9807):1962-73
pubmed: 21492929
Pediatrics. 2014 Aug;134(2):210-7
pubmed: 25002663
Vaccine. 2018 Oct 29;36(45):6883-6891
pubmed: 30244873
Pediatr Infect Dis J. 2014 Jan;33 Suppl 2:S161-71
pubmed: 24336058
J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S352-S359
pubmed: 34590137
Pediatr Infect Dis J. 2013 Mar;32(3):203-7
pubmed: 23558320
MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):253-7
pubmed: 20224541
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD004977
pubmed: 19821336
Pediatr Infect Dis J. 2020 Aug;39(8):763-770
pubmed: 32639460
MMWR Morb Mortal Wkly Rep. 2018 Feb 09;67(5):156-157
pubmed: 29420458
Infect Dis Clin North Am. 2015 Dec;29(4):679-97
pubmed: 26610421
N Engl J Med. 2013 Jul 11;369(2):155-63
pubmed: 23841730
J Infect Dis. 2021 Sep 1;224(12 Suppl 2):S161-S173
pubmed: 34469555
J Infect Dis. 2010 Jan 1;201(1):32-41
pubmed: 19947881
Pediatr Infect Dis J. 2012 Oct;31(10):1016-21
pubmed: 22673142
MMWR Morb Mortal Wkly Rep. 2009 Aug 28;58(33):921-6
pubmed: 19713881
Clin Microbiol Rev. 2012 Jul;25(3):409-19
pubmed: 22763632
Front Microbiol. 2018 Nov 19;9:2670
pubmed: 30524382
Vaccine. 2011 Apr 18;29(18):3398-412
pubmed: 21397721
MMWR Morb Mortal Wkly Rep. 2018 Oct 12;67(40):1123-1128
pubmed: 30307907